Veliparib

The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.

CHICAGO — The addition of veliparib to adjuvant temozolomide did not extend OS or PFS among patients with newly diagnosed MGMT hypermethylated glioblastoma, according to results of a randomized phase 2/phase 3 trial presented at ASCO Annual Meeting.

The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in secondary malignancies among patients with triple-negative breast cancer, randomized phase 3 trial results showed.

Veliparib plus carboplatin/paclitaxel followed by veliparib maintenance showed smaller improvements in health-related quality of life measures from baseline compared with carboplatin/paclitaxel alone among patients with newly diagnosed stage III or IV ovarian cancer.

Research exploring novel targeted agents for patients with metastatic breast cancer is mounting and spurring excitement in the oncology field.